No Association Between IRS2 Gly1057Asp Polymorphism and Esophageal Cancer

Year 2021, Volume: 14 Issue: 3, 298 - 303, 30.12.2021

İsmail Gülaçar Zehra Kaya , Necat Almalı Can Ateş , Gözde Yeşil Sayın , Gökhan Görgişen

https://doi.org/10.52976/vansaglik.933072

Abstract

Introduction: The aim of this study was to figure out the relationship between IRS2 Gly1057Asp variant and susceptibility to esophageal cancer.
Material and Methods: A case-control study was conducted to select 70 esophageal cancer patients and 100 healthy control samples. Genomic DNA was extracted from peripheral whole blood samples and real time polymerase chain reaction (RT-PCR) based SNP genotyping was performed using predesigned Taqman assay.
Results: There was no significant difference in the frequency distribution of genotypes between patients and control group.
Conclusion: There is no significant correlation between the IRS2 Gly1057Asp variant and the risk of esophageal cancer.

Keywords

IRS2 Gly1057Asp, rs1805097, esophageal cancer

IRS2 Gly1057Asp Polimorfizmi ile Özofagus Kanseri Arasında İlişki Yoktur

Abstract

Amaç: Bu çalışmanın amacı IRS2 Gly1057Asp varyantı ile özofagus kanseri yatkınlığı arasındaki ilişkiyi ortaya çıkarmaktır.
Materyal ve Metod: Çalışma 70 özofagus kanseri ve 100 sağlıklı kontrol örneğini içeren vaka-kontrol çalışmasıdır. Genomik DNA, periferal kandan izole edilmiş olup, gerçek zamanlı polimeraz zincir reaksiyonu (RT-PCR) temelli SNP genotipleme için ticari olarak dizayn edilmiş Taqman assay kullanılmıştır.
Bulgular: Genotip dağılımında hasta ve kontrol örnekler arasında anlamlı bir farklılık saptanmamıştır.
Sonuç: IRS2 Gly1057Asp varyantı ile özofagus kanser gelişim riski arasında anlamlı bir ilişki belirlenememiştir.

Keywords

IRS2 Gly1057Asp, rs1805097, Özofagus Kanseri

References

• Alaouna M, Hull R, Penny C, Dlamini Z. Esophageal cancer genetics in South Africa. Clin Exp Gastroenterol. 2019; 12: 157–77.
• Boissan M, Beurel E, Wendum D et al. Overexpression of insulin receptor substrate-2 in human and murine hepatocellular carcinoma. Am J Pathol. 2005; 167: 869–877.
• Cayan F, Dilek S, G Ramazan, Ayaz L. Association of insulin receptor substrate-2 gene polymorphism with ovarian cancer. Balkan Med J. 2011; 28:14-7.
• Cayan F, Tok E, Aras-Ates N et al. Insulin receptor substrate 2 gene polymorphism: is it associated with endometrial cancer? Gynecol Endocrinol. 2010; 26: 378-82.
• Chan BT, Lee AV. Insulin receptor substrates (IRSs) and breast tumorigenesis. J Mammary Gland Biol Neoplasia. 2008; 13: 415–422. D’Alfonso R, Marini MA, Frittitta L et al. Polymorphisms of the insulin receptor substrate-2 in patients with type 2 diabetes. J Clin Endocrinol Metab. 2003; 88: 317-22.
• Day E, Poulogiannis G, McCaughan F et al. IRS2 is a candidate driver oncogene on 13q34 in colorectal cancer. Int J Exp Pathol. 2013; 94: 203–11.
• Dearth RK, Cui X, Kim HJ et al. Mammary tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2. Molecular and Cellular Biology. 2006; 26: 9302-14.
• Gibson SL, Ma Z, Shaw LM. Divergent roles for IRS-1 and IRS- 2 in breast cancer metastasis. Cell Cycle. 2007; 6: 631-637.
• Gorgisen G, Gulacar IM, Ozes ON. The role of insulin receptor substrate (IRS) proteins in oncogenic transformation. Cell Mol Biol (Noisy-le-grand). 2017; 63(1): 1-5.
• Gorgisen G, Hapil FZ, Yilmaz O et al. Identification of novel mutations of Insulin Receptor Substrate 1 (IRS1) in tumor samples of non-small cell lung cancer (NSCLC): Implications for aberrant insulin signaling in development of cancer. Genet Mol Bio. 2019; 42: 15-25.
• Hu Y, Zhou M, Zhang K et al. Lack of association between insulin receptor substrate 2 rs1805097 polymorphism and the risk of colorectal and breast cancer: A meta-analysis. Plos One. 2014; 9: e86911.
• Lautier C, El Mkadem SA, Renard E et al. Complex haplotypes of IRS2 gene are associated with severe obesity and reveal heterogeneity in the effect of Gly1057Asp mutation. Hum Genet. 2003; 113: 34-43.
• Lin DC, Wang MR, Koeffler HP. Genomic and epigenomic aberrations in esophageal squamous cell carcinoma and implications for patients. Gastroenterology. 2018; 154(2): 374-89.
• Lin MW, Huang MF, Wu MH. Association of Gly972Arg variant of insulin receptor subtrate-1 and Gly1057Asp variant of insulin receptor subtrate-2 with polycystic ovary syndrome in the Chinese population. J Ovarian Res. 2014; 7: 92.
• Mammarella S, Romano F, Di Valerio A et al. Interaction between the G1057D variant of IRS-2 and overweight in the pathogenesis of type 2 diabetes. Hum Mol Genet. 2000; 9: 2517-21.
• Nagle JA, Ma Z, Byrne MA, White MF, Shaw LM. Involvement of insulin receptor substrate 2 in mammary tumor metastasis. Molecular and Cellular Biology. 2004; 24: 9726-35.
• Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013; 381(9864): 400-12.
• Piper AJ, Clark JL, Mercado-Matos J et al. Insulin receptor substrate-1 (IRS-1) and IRS-2 expression levels are associated with prognosis in non-small cell lung cancer (NSCLC). PLoS One. 2019 Aug 8;14(8): e0220567.
• Porter HA, Perry A, Kingsley C, Tran NL, Keegan AD. IRS1 is highly expressed in localized breast tumors and regulates the sensitivity of breast cancer cells to chemotherapy, while IRS2 is highly expressed in invasive breast tumors. Cancer Lett. 2013; 338(2): 239-48.
• Wagner K, Hemminki K, Grzybowska E et al. The insulin-like growth factor-1 pathway mediator genes: SHC1 Met300Val shows a protective effect in breast cancer. Carcinogenesis. 2004 Dec; 25(12): 2473-8.
• Yin J, Zhang Z, Zheng H, Xu L. IRS-2 rs1805097 polymorphism is associated with the decreased risk of colorectal cancer. Oncotarget. 2017; 8: 25107–14.
• Yükseloğlu EH, Çelik SK, Kucuk MU et al. IRS-2 G1057D polymorphism in Turkish patients with colorectal cancer. Prz Gastroenterol. 2014; 9: 88-92.